Genmab focuses on products to treat various cancers, where human antibodies are expected to be particularly useful as they should lend themselves to long-term therapy without the risk of rejection by the body's immune system.
Meet Selina Khan. She’s a postdoc in the Leiden University Medical Centre, where she studies the possible role for Toll-like receptors in vaccine immunotherapy. One of her passions is cooking and if she wouldn’t be working in science she would probably do something with her kitchen skills.
